SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media shares are under pressure as traders connect the decline to Trumps reported record-low approval and approaching midterms, while also questioning the companys business fundamentals. Some see the selloff as a speculative buying opportunity, but bearish sentiment dominates.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is drawing attention amid a sharp selloff and mounting concern over its heavy debt, costly financing, and ability to fund AI infrastructure expansion. Bears see refinancing and dilution risks outweighing its AI demand and backlog, while bulls point to those growth prospects and dip buying; a bullish analyst call and ARK purchases have not quelled the debate.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep post-IPO selloff is the dominant topic, with traders pointing to lockup-related share supply, reported insider selling and a TD Cowen price-target cut, alongside concerns about valuation and the companys ability to scale. Sentiment is largely bearish, though some investors view the decline as oversold and are adding to positions.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

CleanSparks steep selloff alongside other bitcoin miners is driving discussion, with traders pointing to financing and debt costs, higher rates, and weak sector sentiment. Bulls argue the Meta-backed AI data-center lease and bitcoin holdings offer longer-term support, while skeptics say those positives have not offset near-term risks or the stocks underperformance.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Anktivas FDA label expansion into papillary-only bladder cancer is the main catalyst, but IBRX has sold off despite the approval and positive trial updates. Bulls characterize the decline as a sell-the-news move or short pressure, while skeptics point to valuation, competition, and the need for revenue growth to support the companys expectations.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Ubers prolonged share-price weakness is driving debate over whether robotaxi competition from Waymo and Tesla threatens its rides business, or whether that risk is overstated given its scale and cash generation. Some traders view the shares as undervalued and welcome the ezCater deal as a boost to delivery, while others remain frustrated by the stocks persistent underperformance.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians prolonged slide to fresh 52-week lows is driving discussion, with traders focused on concerns about cash burn, execution and the R2 production ramp ahead of Q3 earnings, despite stronger deliveries. Some are buying the dip and pointing to R2 progress and VW backing, while others question profitability and whether upcoming results can change sentiment.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale shares are under pressure after UBS downgraded the stock, citing long commercialization timelines and a lack of firm customer commitments. Traders debate whether the selloff is an overreaction or reflects real execution and cash-burn risks, with some expecting a rebound and others questioning whether NuScale can secure projects and deliver reactors.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

Attention centers on the anticipated completion of Compass Pathways rolling FDA application for COMP360, its investigational psilocybin treatment for treatment-resistant depression, and the potential path toward approval and commercialization. Many traders see the regulatory milestone as a catalyst, while others are frustrated by the share-price weakness and uncertainty over the submission timeline and eventual FDA decision.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

EyePoints failed Phase 3 wet-AMD readout has intensified scrutiny of TKI-based treatments and weighed on OCUL, despite arguments that the setback removes a competitor. Traders disagree on whether the results cast doubt on AXPAXLIs prospects or are not comparable because OCUL uses a different molecule and has positive SOL-1 data; attention also centers on its pending NDA and the confirmatory SOL-R study.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders

Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure DisordersPR NewswireSYDNEY, Sept. 22, 2026 Clinical Milestone...

Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer

Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer PR Newswire SYDNEY...

Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy

Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances...

Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer

Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing...

Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering

Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering PR Newswire SYDNEY, Aug. 31, 2026 Company to host a corporate update call Tuesday, September 1st at...

Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering

Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering PR Newswire SYDNEY, Aug. 28, 2026 SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited(NASDAQ: KZIA) ("Kazia" or the...

Kazia Therapeutics Limited Announces Proposed Public Offering

Kazia Therapeutics Limited Announces Proposed Public Offering Kazia Therapeutics Limited Announces Proposed Public Offering PR Newswire SYDNEY, Aug. 27, 2026 SYDNEY, Aug. 27, 2026 /PRNewswire/ -- Kazia Therapeutics Limited(NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology...

Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer

Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer PR Newswire SYDNEY, Aug. 27, 2026 Durable...

The Multi-Billion-Dollar Race to Defeat Glioblastoma: Why Investors Are Watching One of Oncology's Most Challenging Frontiers

Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types. $NTHI, $KZIA, $BNTX, $IBRX

Kazia Therapeutics Appoints James Levine as Chief Financial Officer

Kazia Therapeutics Appoints James Levine as Chief Financial Officer Kazia Therapeutics Appoints James Levine as Chief Financial Officer PR Newswire SYDNEY, June 2, 2026 SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a...

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. It focuses on its Paxalisib program, which is designed to treat brain cancer. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Kazia Therapeutics Limited - ADR

KZIA Stock Is Rising Today — What Does Its Data For Nuclear PD-L1 Degrader Show?

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Kazia stated that in murine triple-negative breast cancer preclinical models, NDL2 reduced primary tumor volume by 49% as monotherapy.</li><li>In combination with the anti-PD-1 therapy, the treatment reduced the volume of the primary tumor by 73%.</li><li>In patients with lung metastases, Kazia stated that NDL2, combined with anti-PD-1 therapy, reduced the primary tumor’s volume by 50%.</li></ul>Kazia Therapeutics Inc.’s (KZIA) shares rose more than 6% in Friday’s pre-market trade after the company announced new preclinical and translational data for NDL2, a protein degrader.The Sydney, Australia-based oncology-focused pharmaceutical company stated that across multiple preclinical models and patient-derived samples, NDL2 demonstrated reversal of immune exhaustion, suppression of metastatic biology, and enhanced anti-tumor activity. This includes the combination of NDL2 with anti-PD-1 therapy, which uses monoclonal bodies such as nivolumab or pembrolizumab to block the PD-1 protein on T-cells.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/KZIA">Kazia Therapeutics</a> was in the ‘bullish’ territory at the time of writing, while message volume was at ‘high’ levels.<h2 class="st-heading-2">Highlights Of New NDL2 Data</h2>Kazia stated that in murine triple-negative breast cancer (TNBC) preclinical models, NDL2 reduced primary tumor volume by 49% as monotherapy. In combination with the anti-PD-1 therapy, the treatment reduced the volume of the primary tumor by 73%.In patients with lung metastases, Kazia stated that NDL2, combined with anti-PD-1 therapy, reduced the primary tumor’s volume by 50%.The company added that no toxicity or hemolysis was observed, while noting that the immune checkpoint function at the cell surface was preserved, and the plasma stability was favorable.<h2 class="st-heading-2">What Is NDL2 Aimed At?</h2>Kazia is currently developing the NDL2 protein degrader to selectively eliminate nuclear PD-L1 (Programmed Death-Ligand 1).PD-L1 is a protein found on the surface of many cancer cells as well as some normal cells. The protein helps these cells evade the immune system.<a href="https://stocktwits.com/symbol/KZIA">KZIA stock</a> is down 6% year-to-date and 12% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sofi-stock-rises-after-sofi-technologies-reports-1b-quarterly-revenue-first-time/cmySKHPR4ST">SOFI Stock Rises Pre-Market After SoFi Technologies Reports $1B Quarterly Revenue For The First Time</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

Kazia stated that across multiple preclinical models and patient-derived samples, NDL2 demonstrated reversal of immune exhaustion, suppression of metastatic biology, and enhanced anti-tumor activity.

iShares U.S. Pharmaceuticals ETF

Kazia Therapeutics

VanEck Pharmaceutical ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$7.85
Prev Close	$7.25
Open	$7.42
Dividend Yield	N/A
50-Day Moving Average	$11.22
Beta	1.53
Avg. Volume	334,953.82
PE Ratio	-1.15

52-Week High	$17.40
52-Week Low	$4.86
Market Capitalization	$89.7M
EPS (Annual)	N/A
Price to Book	2.87
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

KZIA Fundamentals